Anish Bhatnagar 4

What Happened

• Anish Bhatnagar, CEO of Soleno Therapeutics (SLNO), received equity awards on 2026-01-21: 114,200 restricted stock units (RSUs) and 131,400 RSUs (reported as a derivative award). Both awards were granted at $0.00 (no cash exchanged), for a total of 245,600 RSUs awarded.
• These are awards (code A on the Form 4). One set (114,200 RSUs) is subject to a single vesting date; the other set is described as RSUs subject to applicable vesting schedules and conditions.

Key Details

• Transaction date: 2026-01-21; filing date: 2026-01-23 (filed timely).
• Grant price: $0.00 per RSU; total immediate cash value reported: $0.
• Total RSUs granted: 114,200 + 131,400 = 245,600 RSUs.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: The 114,200 RSUs vest 100% on December 15, 2027, contingent on continued service.
  • F2: The 131,400 RSUs are RSUs subject to the applicable vesting schedule and conditions of each RSU.
  • F3: Separately, certain option awards held by the reporting person vest 1/48th monthly beginning Feb 1, 2026 (this describes existing option vesting, not the new RSU grants).
• Transaction type: Award/Grant (A). These are contingent RSUs, not immediate shares.

Context

• RSUs are contingent rights to receive common stock upon vesting; they do not represent immediate ownership or a cash purchase signal. Vesting schedules determine when the CEO will actually receive shares.
• This filing reports newly granted compensation equity to the CEO and was filed within the SEC’s required timeframe.